Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Avalon Trust Co

Avalon Trust Co boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,297 shares of the medical research company’s stock after acquiring an additional 495 shares during the period. Thermo Fisher Scientific comprises about 1.8% of Avalon Trust Co’s investment portfolio, making the stock its 20th biggest holding. Avalon Trust Co’s holdings in Thermo Fisher Scientific were worth $19,266,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. International Assets Investment Management LLC grew its position in shares of Thermo Fisher Scientific by 61,995.4% during the fourth quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock worth $535,923,000 after acquiring an additional 1,008,045 shares during the last quarter. Loomis Sayles & Co. L P grew its holdings in Thermo Fisher Scientific by 17,046.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company’s stock worth $492,803,000 after buying an additional 967,913 shares in the last quarter. Van ECK Associates Corp raised its stake in Thermo Fisher Scientific by 2,567.5% during the 4th quarter. Van ECK Associates Corp now owns 352,217 shares of the medical research company’s stock valued at $186,954,000 after acquiring an additional 339,013 shares in the last quarter. Rathbones Group PLC boosted its position in Thermo Fisher Scientific by 111.0% during the 3rd quarter. Rathbones Group PLC now owns 568,970 shares of the medical research company’s stock worth $287,996,000 after acquiring an additional 299,338 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Thermo Fisher Scientific by 20.3% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,706,179 shares of the medical research company’s stock valued at $863,617,000 after purchasing an additional 287,446 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 5,547 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the completion of the sale, the chief executive officer now owns 43,608 shares in the company, valued at $24,011,436.96. The disclosure for this sale can be found here. Insiders have sold a total of 62,277 shares of company stock worth $35,373,364 over the last three months. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.2 %

TMO traded up $1.13 during trading on Friday, reaching $572.38. 1,749,670 shares of the stock traded hands, compared to its average volume of 1,409,187. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The stock’s 50-day simple moving average is $575.39 and its two-hundred day simple moving average is $532.82. The stock has a market cap of $218.48 billion, a price-to-earnings ratio of 36.71, a price-to-earnings-growth ratio of 2.37 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TMO shares. Citigroup began coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They set a “neutral” rating and a $620.00 price target for the company. Royal Bank of Canada upped their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Robert W. Baird cut their price objective on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Evercore ISI boosted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Finally, JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $607.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.